Combination Product Submissions Rose 10% In FY 2005 – FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA received 275 applications for combination products in fiscal year 2005, a 10% increase over the prior year, according to a May 29 report to Congress
You may also be interested in...
FDA Proposes Streamlining Intercenter Agreements On Combo Products
FDA is proposing to rescind an intercenter agreement between the Center for Biologics Evaluation & Research (CBER) and the Center for Drug Evaluation & Research (CDER) in order to modernize its oversight of combination products
FDA Proposes Streamlining Intercenter Agreements On Combo Products
FDA is proposing to rescind an intercenter agreement between the Center for Biologics Evaluation & Research (CBER) and the Center for Drug Evaluation & Research (CDER) in order to modernize its oversight of combination products
MDUFMA Addresses In Vitro Diagnostics, Combination Product Regulation
FDA will be required to report to Congress on Center for Biologics Evaluation & Research review times for in vitro diagnostics under the "Medical Device User Fee and Modernization Act" of 2002 (MDUFMA), which cleared the House Energy & Commerce Committee Oct. 2